RTI Surgical (RTIX) Posts Q2 Loss of 5c/Share; Will Conduct Strategic Business Review

Go back to RTI Surgical (RTIX) Posts Q2 Loss of 5c/Share; Will Conduct Strategic Business Review

Craig-Hallum Downgrades RTI Biologics (RTIX) to Hold

July 28, 2016 8:46 AM EDT

Craig-Hallum downgraded RTI Biologics (NASDAQ: RTIX) from Buy to Hold with a price target of $4.00 (from $6.00).

For an analyst ratings summary and ratings history on RTI Biologics click here. For more ratings news on RTI Biologics click here.

Shares of RTI Biologics closed at $3.43 yesterday.

... More